诊断并治疗引起缺血的冠状动脉狭窄可改善接受大血管手术患者的5年生存
本观察性队列研究纳入522例无已知冠心病行择期颈动脉、外周或动脉瘤手术患者,比较术前冠状动脉CT血管成像及FFRCT指导组(288例)与常规评估对照组(234例)。FFRCT组5年全因死亡16% vs 36%(HR 0.37),心血管死亡4% vs 21%(HR 0.11),心肌梗死4% vs 24%(HR 0.13),主要不良心血管事件20% vs 47%(HR 0.36),5年生存率84% vs 64%(P < .001)。
要点
- FFRCT组65%患者存在无症状病变特异性冠状动脉缺血,严重缺血占52%。
- FFRCT组5年全因死亡16% vs 对照组36%(HR 0.37,95%CI 0.22-0.60)。
- FFRCT组5年生存率84% vs 对照组64%(P < .001)。
核心结论
- 大血管手术后诊断无症状冠状动脉缺血并针对缺血行冠状动脉血运重建联合最佳药物治疗,与仅按当前指南接受最佳药物治疗相比,不良心血管事件更少且5年生存改善。
研究设计与样本
- 观察性队列研究,纳入522例无已知冠心病行择期颈动脉、外周或动脉瘤手术患者,FFRCT指导组288例,匹配对照组234例。
主要发现
- FFRCT组65%患者存在无症状病变特异性冠状动脉缺血,严重缺血52%,多支血管缺血36%,左主干缺血8%。
- 5年时FFRCT组与对照组比较:全因死亡16% vs 36%(HR 0.37,95%CI 0.22-0.60,P < .001)。
- 心血管死亡4% vs 21%(HR 0.11,95%CI 0.04-0.33,P < .001)。
- 心肌梗死4% vs 24%(HR 0.13,95%CI 0.05-0.33,P < .001)。
- 主要不良心血管事件20% vs 47%(HR 0.36,95%CI 0.23-0.56,P < .001)。
关键数值与推荐
- FFRCT组病变特异性冠状动脉缺血定义为冠状动脉狭窄远端FFRCT ≤0.80,严重缺血定义为FFRCT ≤0.75。
- FFRCT组103例患者在术后1至3个月接受择期缺血靶向冠状动脉血运重建。
临床怎么用
- 作者结论认为,大血管手术后以FFRCT诊断无症状冠状动脉缺血并针对缺血行冠状动脉血运重建联合最佳药物治疗,与仅用最佳药物治疗相比与更少不良心血管事件和更好5年生存相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Patients undergoing vascular surgery procedures have poor long-term survival due to coexisting coronary artery disease (CAD), which is often asymptomatic, undiagnosed, and undertreated. We sought to determine whether preoperative diagnosis of asymptomatic (silent) coronary ischemia using coronary computed tomography (CT)-derived fractional flow reserve (FFRCT) together with postoperative ischemia-targeted coronary revascularization can reduce adverse cardiac events and improve long-term survival following major vascular surgery METHODS: In this observational cohort study of 522 patients with no known CAD undergoing elective carotid, peripheral, or aneurysm surgery we compared two groups of patients. Group I included 288 patients enrolled in a prospective Institutional Review Board-approved study of preoperative coronary CT angiography (CTA) and FFRCT testing to detect silent coronary ischemia with selective postoperative coronary revascularization in addition to best medical therapy (BMT) (FFRCT guided), and Group II included 234 matched controls with standard preoperative cardiac evaluation and postoperative BMT alone with no elective coronary revascularization (Usual Care). In the FFRCT group, lesion-specific coronary ischemia was defined as FFRCT ≤0.80 distal to a coronary stenosis, with severe ischemia defined as FFRCT ≤0.75. Results were available for patient management decisions. Endpoints included all-cause death, cardiovascular death, myocardial infarction (MI), and major adverse cardiovascular events (MACE [death, MI, or stroke]) during 5-year follow-up. RESULTS: The two groups were similar in age, gender, and comorbidities. In FFRCT, 65% of patients had asymptomatic lesion-specific coronary ischemia, with severe ischemia in 52%, multivessel ischemia in 36% and left main ischemia in 8%. The status of coronary ischemia was unknown in Usual Care. Vascular surgery was performed as planned in both cohorts with no difference in 30-day mortality. In FFRCT, elective ischemia-targeted coronary revascularization was performed in 103 patients 1 to 3 months following surgery. Usual Care had no elective postoperative coronary revascularizations. At 5 years, compared with Usual Care, FFRCT guided had fewer all-cause deaths (16% vs 36%; hazard ratio [HR], 0.37; 95% confidence interval [CI], 0.22-0.60; P < .001), fewer cardiovascular deaths (4% vs 21%; HR, 0.11; 95% CI, 0.04-0.33; P < .001), fewer MIs (4% vs 24%; HR, 0.13; 95% CI, 0.05-0.33; P < .001), and fewer MACE (20% vs 47%; HR, 0.36; 95% CI, 0.23-0.56; P < .001). Five-year survival was 84% in FFRCT compared with 64% in Usual Care (P < .001). CONCLUSIONS: Diagnosis of silent coronary ischemia with ischemia-targeted coronary revascularization in addition to BMT following major vascular surgery was associated with fewer adverse cardiovascular events and improved 5-year survival compared with patients treated with BMT alone as per current guidelines.
引用
- Krievins DK, Zellans E, Latkovskis G, et al. Diagnosis and treatment of ischemia-producing coronary stenoses improves 5-year survival of patients undergoing major vascular surgery. J Vasc Surg. 2024. PMID: 38518962. doi:10.1016/j.jvs.2024.02.043
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。